O36.013 Maternal care for anti-D [Rh] antibodies, third trimester

Name of the Condition

• Maternal care for anti-D [Rh] antibodies, third trimester
• ICD Code: O36.013

Summary

This condition involves medical care and monitoring provided to a pregnant woman during the third trimester who has anti-D (Rh) antibodies. The focus is on managing the risk of hemolytic disease in the fetus or newborn, which can occur if the fetus is Rh-positive. Care includes assessment of antibody levels, fetal monitoring, and planning for potential interventions to prevent or treat complications.

Causes

The presence of anti-D antibodies typically results from prior exposure to Rh-positive blood, such as during a previous pregnancy with an Rh-positive fetus, blood transfusion, or trauma. These antibodies can cross the placenta and attack the red blood cells of an Rh-positive fetus, leading to hemolysis.

Risk Factors

• Previous pregnancy with an Rh-positive fetus
• Blood transfusion with Rh-positive blood
• Trauma or procedures (e.g., amniocentesis) during pregnancy that may cause fetal-maternal bleeding
• Unknown prior sensitization (e.g., from unrecognized fetal-maternal hemorrhage)

Symptoms

• No direct maternal symptoms; the condition is identified through laboratory testing
• Potential fetal complications (e.g., anemia, hydrops fetalis) may develop, but these are not maternal symptoms

Diagnosis

Diagnosis involves testing the mother’s blood for anti-D antibodies, typically through antibody screening and titers. Fetal monitoring may include Doppler ultrasound to assess for anemia or other signs of hemolysis. Additional testing, such as amniocentesis or cordocentesis, may be performed if severe fetal compromise is suspected.

Treatment Options

Treatment depends on the severity of the condition and fetal status. Options may include close monitoring, intrauterine transfusions for the fetus if anemia is present, and planning for early delivery if complications arise. Rh immunoglobulin (RhoGAM) is not used in sensitized pregnancies but may be considered in future pregnancies to prevent further sensitization.

Prognosis and Follow-Up

With appropriate monitoring and intervention, outcomes for both mother and fetus can be favorable. Follow-up involves regular assessment of antibody levels and fetal well-being until delivery. Postpartum care includes evaluating the newborn for signs of hemolytic disease and providing necessary treatment, such as phototherapy or exchange transfusion.

Complications

• Severe fetal anemia
• Hydrops fetalis (fluid accumulation in fetal tissues)
• Kernicterus (brain damage from severe jaundice)
• Preterm birth or stillbirth in severe cases

Lifestyle & Prevention

• Ensure proper prenatal care and adherence to recommended monitoring schedules.
• Avoid unnecessary procedures that may increase fetal-maternal blood mixing.
• Discuss future pregnancy planning with a healthcare provider to manage Rh sensitization risks.

When to Seek Professional Help

Seek immediate medical attention if there are signs of fetal distress, such as reduced fetal movement, or if maternal symptoms (e.g., severe abdominal pain) occur. Regular prenatal visits are essential for ongoing monitoring.

Tips for Medical Coders

Document the trimester (third trimester) and the presence of anti-D antibodies clearly. Ensure the code O36.013 is used when the care is specifically for the third trimester and aligns with the clinical scenario. Verify that the documentation supports the need for maternal care related to Rh antibody management during this period.